Nov 20, 2015 2 min read

CANONSBURG — Mylan N.V. said Friday that its Mylan Laboratories Limited subsidiary completed the acquisition of certain women’s healthcare businesses, now known as Jai Pharma, which were spun off from Famy Care Limited.

The company said in a press release that the transaction brings it a broad women’s care portfolio, strong technical capabilities and dedicated hormone manufacturing.

Mylan said that when combined with Mylan’s expansive global commercial footprint and supply chain infrastructure, the new assets will create a leading women’s healthcare franchise.

“The completion of this transaction is an important milestone as we continue to grow our global women’s healthcare franchise, and take another step in our mission to provide the world’s 7 billion people access to high quality medicine,” said Mylan CEO Heather Bresch. “In addition to strengthening our women’s healthcare offering in North America, we will continue to leverage our powerful commercial platform in Europe, now enhanced through our recent Abbott deal, to serve this important therapeutic area.

Bresch added that the expanded portfolio”Moreover, we look fo will also enable Mylan to build upon its existing commercial presence in emerging markets.

“This will include building upon our existing women’s care portfolio in India and expanding our reach in support of Family Planning 2020, a global partnership that aims to enable 120 million more women and girls to use contraceptives by 2020,” she said.

According to Bresch, the acquistion will add nearly 1,000 employees to Mylan.

The company said the acquisition is expected to be immediately accretive to its adjusted diluted earnings per share and that Mylan’s financial leverage is not materially altered as a result of this transaction.